Dimensional Fund Advisors LP lowered its position in PerkinElmer, Inc. (NYSE:PKI) by 0.2% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 759,559 shares of the medical research company’s stock after selling 1,790 shares during the quarter. Dimensional Fund Advisors LP owned about 0.69% of PerkinElmer worth $55,617,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Twin Tree Management LP increased its holdings in PerkinElmer by 135.8% in the 2nd quarter. Twin Tree Management LP now owns 2,549 shares of the medical research company’s stock worth $187,000 after acquiring an additional 9,674 shares during the last quarter. Cambridge Investment Research Advisors Inc. purchased a new position in PerkinElmer during the 1st quarter valued at about $203,000. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. purchased a new position in PerkinElmer during the 1st quarter valued at about $204,000. Janney Montgomery Scott LLC purchased a new position in PerkinElmer during the 2nd quarter valued at about $249,000. Finally, Oakbrook Investments LLC purchased a new position in PerkinElmer during the 2nd quarter valued at about $300,000. 95.78% of the stock is owned by institutional investors.

In other news, CEO Robert F. Friel sold 2,709 shares of the business’s stock in a transaction dated Wednesday, August 1st. The stock was sold at an average price of $80.00, for a total transaction of $216,720.00. Following the completion of the transaction, the chief executive officer now owns 575,366 shares of the company’s stock, valued at $46,029,280. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Joel S. Goldberg sold 34,608 shares of the business’s stock in a transaction dated Thursday, August 2nd. The stock was sold at an average price of $85.00, for a total value of $2,941,680.00. The disclosure for this sale can be found here. Insiders have sold 67,177 shares of company stock valued at $5,826,167 in the last three months. 2.10% of the stock is owned by insiders.

PKI stock opened at $96.26 on Wednesday. PerkinElmer, Inc. has a twelve month low of $67.51 and a twelve month high of $97.51. The company has a quick ratio of 1.17, a current ratio of 1.69 and a debt-to-equity ratio of 0.79. The stock has a market cap of $10.70 billion, a price-to-earnings ratio of 33.19, a P/E/G ratio of 2.14 and a beta of 1.01.

PerkinElmer (NYSE:PKI) last issued its quarterly earnings data on Wednesday, August 1st. The medical research company reported $0.91 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.86 by $0.05. PerkinElmer had a return on equity of 14.25% and a net margin of 5.51%. The company had revenue of $703.55 million during the quarter, compared to analyst estimates of $694.70 million. During the same quarter in the previous year, the firm earned $0.67 earnings per share. PerkinElmer’s revenue was up 28.6% on a year-over-year basis. sell-side analysts expect that PerkinElmer, Inc. will post 3.65 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 9th. Stockholders of record on Friday, October 19th will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.29%. The ex-dividend date is Thursday, October 18th. PerkinElmer’s payout ratio is 9.66%.

A number of research analysts have weighed in on PKI shares. Barclays lifted their target price on PerkinElmer from $73.00 to $79.00 and gave the company an “underweight” rating in a report on Thursday, August 2nd. Zacks Investment Research lowered PerkinElmer from a “buy” rating to a “hold” rating in a report on Monday, June 4th. Deutsche Bank lifted their target price on PerkinElmer from $88.00 to $93.00 and gave the company a “hold” rating in a report on Monday, September 10th. Morgan Stanley lifted their target price on PerkinElmer from $90.00 to $95.00 and gave the company an “overweight” rating in a report on Thursday, August 2nd. Finally, ValuEngine raised PerkinElmer from a “hold” rating to a “buy” rating in a report on Thursday, July 26th. Nine research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $82.53.

PerkinElmer Company Profile

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil.

Featured Article: What is the Dividend Aristocrat Index?

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.